USE OF RITUXIMAB IN PATIENTS WITH SYSTEMIC MANIFESTATIONS OF PRIMARY SJOGREN'S SYNDROME

The data on the efficacy of rituximab (RTM) in systemic manifestations of primary Sjogren's syndrome (PSS) are limited by single trials.Objective: to evaluate the efficacy of RTM in patients with the systemic manifestations of PSS.Subjects and methods. RTM therapy was performed in 24 patients w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: O. A. Logvinenko, V. I. Vasilyev, T. N. Safonova, E. B. Rodionova, E. N. Aleksandrova
Formato: Artigo
Idioma:Russo
Publicado em: IMA-PRESS LLC 2014-12-01
Colecção:Научно-практическая ревматология
Assuntos:
rituximab
primary sjogren's syndrome
cryoglobulinemic vasculitis
Acesso em linha:https://rsp.mediar-press.net/rsp/article/view/2006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados